Altimmune, Inc.

Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing new treatments for serious liver diseases. The company's main product candidate is pemvidutide (formerly ALT-801), a balanced 1:1 glucagon/GLP-1 dual receptor agonist. Pemvidutide is being developed to treat metabolic dysfunction-associated steatohepatitis ("MASH"), alcohol use disorder ("AUD"), and alcohol-associated liver disease ("ALD"). Altimmune may also explore other uses for pemvidutide based on its clinical profile. Altimmune acquired pemvidutide through the acquisition of Spitfire Pharma Inc. in July 2019. Pemvidutide was designed as a MASH therapeutic to target both metabolic and liver-specific effects. Preclinical studies in a mouse model of MASH showed efficacy. In initial human trials, pemvidutide demonstrated weight loss and liver effects. Subsequent evaluation in participants with fatty liver disease, or metabolic-dysfunction associated liver disease (MASLD), showed significant reductions in liver fat content and weight loss. These findings led to the biopsy-driven IMPACT Phase 2b trial for MASH. The MOMENTUM Phase 2 trial in overweight and obese participants further characterized pemvidutide's effects, showing significant weight loss with relative preservation of lean muscle mass and improvements in serum lipids linked to cardiovascular disease. Beyond the recently completed IMPACT trial, pemvidutide is currently being studied in participants with AUD and ALD, with evidence suggesting it may reduce alcohol cravings and potentially reverse alcohol's harmful effects on the liver. Pemvidutide is a novel, investigational peptide.